{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:48:00Z","timestamp":1759538880765,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.radonc.2025.111038","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T02:59:44Z","timestamp":1751684384000},"page":"111038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["High-volume biopsy core involvement is not associated with failure after SBRT monotherapy for intermediate-risk prostate cancer"],"prefix":"10.1016","volume":"211","author":[{"given":"Joshua C.","family":"Hurwitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan A.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vianca F.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang-Ming","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert","family":"Lepor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Taneja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Zelefsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3714-7757","authenticated-orcid":false,"given":"Jonathan W.","family":"Lischalk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.radonc.2025.111038_b0005","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2004.01.164","article-title":"Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease","volume":"22","author":"D\u2019Amico","year":"2004","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"6","key":"10.1016\/j.radonc.2025.111038_b0010","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.eururo.2013.03.033","article-title":"A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy","volume":"64","author":"Zumsteg","year":"2013","journal-title":"Eur Urol."},{"issue":"6","key":"10.1016\/j.radonc.2025.111038_b0015","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1097\/01.ju.0000065588.82511.06","article-title":"Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database","volume":"169","author":"Freedland","year":"2003","journal-title":"J Urol."},{"issue":"6","key":"10.1016\/j.radonc.2025.111038_b0020","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/S0022-5347(05)66933-9","article-title":"The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: implications for treatment selection","volume":"164","author":"Gao","year":"2000","journal-title":"J Urol."},{"key":"10.1016\/j.radonc.2025.111038_b0025","unstructured":"Schaeffer EM, Srinivas S, Adra N, et al. Prostate Cancer. NCCN Clin Pract Guidel Oncol NCCN Guidel. 2024;Verson 1.2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"10.1016\/j.radonc.2025.111038_b0030","article-title":"Outcomes of active surveillance for the management of clinically localized prostate cancer in the prospective, multi-institutional Canary PASS cohort","volume":"195(2):313","author":"Newcomb","year":"2015","journal-title":"J Urol."},{"issue":"4","key":"10.1016\/j.radonc.2025.111038_b0035","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1464-410X.2012.11127.x","article-title":"Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models","volume":"111","author":"Iremashvili","year":"2013","journal-title":"BJU Int."},{"issue":"8","key":"10.1016\/j.radonc.2025.111038_b0040","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol."},{"issue":"10196","key":"10.1016\/j.radonc.2025.111038_b0045","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet Lond Engl."},{"issue":"15","key":"10.1016\/j.radonc.2025.111038_b0050","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.radonc.2025.111038_b0055","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.clon.2007.02.007","article-title":"Is the alpha\/beta value for prostate tumours low enough to be safely used in clinical trials?","volume":"19","author":"Da\u015fu","year":"2007","journal-title":"Clin Oncol R Coll Radiol G B."},{"key":"10.1016\/j.radonc.2025.111038_b0060","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13014-023-02397-z","article-title":"High-volume prostate biopsy core involvement is not associated with an increased risk of cancer recurrence following 5-fraction stereotactic body radiation therapy monotherapy","volume":"19","author":"Lischalk","year":"2024","journal-title":"Radiat Oncol Lond Engl."},{"issue":"4","key":"10.1016\/j.radonc.2025.111038_b0065","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"2","key":"10.1016\/j.radonc.2025.111038_b0070","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0022-5347(01)65876-2","article-title":"Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate Cancer: The relationship between nadir level and disease-free survival","volume":"156","author":"Lee","year":"1996","journal-title":"J Urol."},{"issue":"5","key":"10.1016\/j.radonc.2025.111038_b0075","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.ijrobp.2008.12.067","article-title":"Postradiotherapy 2-Year Prostate-Specific Antigen Nadir as a Predictor of Long-Term Prostate Cancer Mortality. Int","volume":"75","author":"Zelefsky","year":"2009","journal-title":"J Radiat Oncol."},{"issue":"1","key":"10.1016\/j.radonc.2025.111038_b0080","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/cncr.22341","article-title":"Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death","volume":"109","author":"Alc\u00e1ntara","year":"2007","journal-title":"Cancer."},{"issue":"2","key":"10.1016\/j.radonc.2025.111038_b0085","doi-asserted-by":"crossref","first-page":"57.e15","DOI":"10.1016\/j.urolonc.2021.06.025","article-title":"The impact of time to prostate specific antigen nadir on biochemical recurrence and mortality rates after radiation therapy for localized prostate cancer","volume":"40","author":"Wenzel","year":"2022","journal-title":"Urol Oncol."},{"key":"10.1016\/j.radonc.2025.111038_b0090","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. Published online 2023. https:\/\/www.R-project.org\/."},{"issue":"1","key":"10.1016\/j.radonc.2025.111038_b0095","doi-asserted-by":"crossref","first-page":"570","DOI":"10.32614\/RJ-2021-053","article-title":"Reproducible Summary Tables with the gtsummary Package","volume":"13","author":"Sjoberg","year":"2021","journal-title":"R J."},{"key":"10.1016\/j.radonc.2025.111038_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v040.i03","article-title":"Dates and Times Made Easy with lubridate","volume":"40","author":"Grolemund","year":"2011","journal-title":"J Stat Softw."},{"key":"10.1016\/j.radonc.2025.111038_b0105","unstructured":"Therneau TM. A package for suvival analysis in R. Published online 2024. https:\/\/CRAN.R-project.org\/package=survival."},{"key":"10.1016\/j.radonc.2025.111038_b0110","unstructured":"Sjoberg DD, Baillie M, Haesendonckx S, Treis T. ggsurvfit: Flexible Time-to-Event Figures. Published online 2024. https:\/\/github.com\/pharmaverse\/ggsurvfit."},{"key":"10.1016\/j.radonc.2025.111038_b0115","doi-asserted-by":"crossref","unstructured":"Wickham H. Ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York; 2016. https:\/\/ggplot2.tidyverse.org.","DOI":"10.1007\/978-3-319-24277-4_9"},{"key":"10.1016\/j.radonc.2025.111038_b0120","doi-asserted-by":"crossref","unstructured":"Qian Y, Feng FY, Halverson S, Blas K, Sandler HM, Hamstra DA. The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy. Int J Radiat Oncol Biol Phys. 2011;81(3):e135-142. doi:10.1016\/j.ijrobp.2011.01.007.","DOI":"10.1016\/j.ijrobp.2011.01.007"},{"issue":"4","key":"10.1016\/j.radonc.2025.111038_b0125","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ijrobp.2011.09.043","article-title":"Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?","volume":"83","author":"Huang","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"10.1016\/j.radonc.2025.111038_b0130","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijrobp.2018.12.045","article-title":"Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer","volume":"104","author":"Zelefsky","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.radonc.2025.111038_b0135","first-page":"33","article-title":"Predictors for post-treatment biopsy outcomes after prostate stereotactic body radiotherapy. Radiother Oncol J Eur Soc Ther Radiol","volume":"159","author":"Zelefsky","year":"2021","journal-title":"Oncol."},{"issue":"1","key":"10.1016\/j.radonc.2025.111038_b0140","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0022-5347(05)67998-0","article-title":"The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy","volume":"163","author":"Sebo","year":"2000","journal-title":"J Urol."},{"issue":"4","key":"10.1016\/j.radonc.2025.111038_b0145","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1464-410X.2009.08774.x","article-title":"The independent value of tumour volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease","volume":"105","author":"Porten","year":"2010","journal-title":"BJU Int."},{"issue":"5","key":"10.1016\/j.radonc.2025.111038_b0150","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.eururo.2009.07.027","article-title":"Should pathologists routinely report prostate tumour volume? The prognostic value of tumour volume in prostate cancer","volume":"57","author":"Wolters","year":"2010","journal-title":"Eur Urol."},{"issue":"2","key":"10.1016\/j.radonc.2025.111038_b0155","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.urology.2007.03.062","article-title":"Tumor volume does not predict for biochemical recurrence after radical prostatectomy in patients with surgical Gleason score 6 or less prostate cancer","volume":"70","author":"Merrill","year":"2007","journal-title":"Urology"},{"issue":"9","key":"10.1016\/j.radonc.2025.111038_b0160","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1245\/s10434-013-3016-4","article-title":"Tumor volume adds prognostic value in patients with organ-confined prostate cancer","volume":"20","author":"Kim","year":"2013","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"10.1016\/j.radonc.2025.111038_b0165","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.juro.2017.10.029","article-title":"Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance","volume":"199","author":"Tosoian","year":"2018","journal-title":"J Urol."},{"issue":"1","key":"10.1016\/j.radonc.2025.111038_b0170","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.juro.2010.08.082","article-title":"A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial","volume":"185","author":"Wolters","year":"2011","journal-title":"J Urol."},{"issue":"7","key":"10.1016\/j.radonc.2025.111038_b0175","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"key":"10.1016\/j.radonc.2025.111038_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110568","article-title":"Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial","volume":"201","author":"Draulans","year":"2024","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol."},{"issue":"1","key":"10.1016\/j.radonc.2025.111038_b0185","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.urology.2013.07.056","article-title":"The percentage of core involved by cancer is the best predictor of insignificant prostate cancer, according to an updated definition (tumor volume up to 2.5 cm3): analysis of a cohort of 210 consecutive patients with low-risk disease","volume":"83","author":"Antonelli","year":"2014","journal-title":"Urology."},{"key":"10.1016\/j.radonc.2025.111038_b0190","article-title":"Cancer Core Length from Targeted Biopsy: An Index of Prostate Cancer Volume and Pathologic Stage","volume":"124(2):275","author":"Simopoulos","year":"2019","journal-title":"BJU Int."},{"issue":"2","key":"10.1016\/j.radonc.2025.111038_b0195","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ijrobp.2023.04.010","article-title":"Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology\/RTOG 0126 Randomized Phase 3 Trial","volume":"117","author":"Spratt","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"6","key":"10.1016\/j.radonc.2025.111038_b0200","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2017.74.2940","article-title":"Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer","volume":"36","author":"Spratt","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"key":"10.1016\/j.radonc.2025.111038_b0205","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.euros.2022.12.002","article-title":"Prostate Cancer Tumor Volume and Genomic Risk","volume":"48","author":"Ramaswamy","year":"2023","journal-title":"Eur Urol Open Sci."},{"issue":"9","key":"10.1016\/j.radonc.2025.111038_b0210","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.clon.2022.05.002","article-title":"Absolute Percentage of Pattern 4 Disease as a Prognostic Measure for Intermediate-risk Prostate Cancer Treated with Stereotactic Body Radiotherapy","volume":"34","author":"Glicksman","year":"2022","journal-title":"Clin Oncol R Coll Radiol G B."},{"issue":"1","key":"10.1016\/j.radonc.2025.111038_b0215","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41746-022-00613-w","article-title":"Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials","volume":"5","author":"Esteva","year":"2022","journal-title":"NPJ Digit Med."}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025045426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025045426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:03:55Z","timestamp":1759521835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025045426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":43,"alternative-id":["S0167814025045426"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111038","relation":{},"ISSN":["0167-8140"],"issn-type":[{"type":"print","value":"0167-8140"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-volume biopsy core involvement is not associated with failure after SBRT monotherapy for intermediate-risk prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111038"}}